Key Insights
- Medpace earnings rose as third-quarter revenue increased 8.5% to $716.0 million.
- Net income climbed 23.7% to $137.5 million, while EBITDA increased 16.0% to $172.1 million.
- Quarterly new business awards reached a record $873.4 million as management narrowed its 2026 revenue outlook.
Medpace earnings showed higher revenue, profit and clinical-trial awards for the quarter ended September 30. The contract research organization released the results October 21, separating the reporting date from the financial period.
Revenue reached $716.0 million, up from $659.9 million one year earlier. The 8.5% increase accompanied wider profit margins and record quarterly new business awards.
Medpace Earnings Lift Net Income 23.7%
GAAP net income increased to $137.5 million from $111.1 million. Diluted earnings rose to $4.84 per share from $3.86, while the net income margin widened to 19.2% from 16.8%.
EBITDA reached $172.1 million, a 16.0% increase from $148.4 million. Its EBITDA margin expanded to 24.0% from 22.5%, showing that profit grew faster than revenue.
| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | $716.0M | $659.9M |
| Net income | $137.5M | $111.1M |
| EBITDA | $172.1M | $148.4M |
| Diluted EPS | $4.84 | $3.86 |
Record Awards Support Backlog Visibility
New business awards entering backlog totaled $873.4 million for the quarter. That figure increased 10.6% from the prior-year period and set a quarterly company record.
Backlog reached approximately $3.17 billion, offering visibility into contracted work that has not yet become revenue. However, award timing, cancellations and trial execution can change how quickly backlog converts into reported sales.
The result adds another signal from the medical research market. Recent Fusion coverage includes Tempus AI’s data agreements and LivaNova’s VNS study results.
Medpace Earnings Narrow 2026 Revenue Guidance
Management now expects 2026 revenue of $2.835 billion to $2.855 billion. The range represents projected growth of 12.0% to 12.8% from 2025 revenue of $2.530 billion.
Medpace forecast full-year net income of $514 million to $524 million and EBITDA of $638 million to $652 million. Diluted EPS guidance stands at $17.97 to $18.32.
Investors should compare awards, backlog conversion, margins and cash generation rather than treating one headline metric as decisive. Fusion Market News’ earnings report guide explains how those measures fit together.
This article is for informational purposes only and does not constitute financial advice. Stock prices can be volatile, and readers should conduct independent research before investing.
Primary source: Medpace third-quarter 2026 results.
Elsy kanana
Elsy Kanana is a financial and cryptocurrency journalist at FusionMarketNews, covering digital assets, blockchain technology, financial markets, and emerging fintech trends. Her reporting focuses on market movements, regulatory developments, and on-chain analytics, delivering clear, data-driven insights to readers worldwide.
